Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05527717 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Revascularization Strategy of Multivessel Disease for Patients with Acute Myocardial Infarction Complicated by Cardiogenic Shock Undergoing Veno-arterial Extracorporeal Membrane Oxygenator

Study acronym: RESCUE-SHOCK
StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study Identification, Study Status, Oversightv4
  2. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Oct 31, 2022 to Nov 16, 2022
    v3
  3. Start date: Sep 15, 2022 to Oct 31, 2022v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is a prospective, open-label, two-arm, randomized multicenter trial to identify whether immediate multi-vessel PCI would be better in clinical outcomes compared with culprit lesion-only PCI for AMI and multi-vessel disease with an advanced form of CS patients who require veno-arterial extracorporeal membrane oxygenator (VA-ECMO).
Trial Details
NCT Number NCT05527717
Lead Sponsor Samsung Medical Center
Conditions
(from sponsor)		 Cardiogenic Shock, Acute Myocardial Infarction, Multi Vessel Coronary Artery Disease, Extracorporeal Membrane Oxygenation
Related terms Shock, Cardiogenic
Enrollment 560 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov